^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    DT2216

    i
    Company:
    Dialectic Therap
    Drug class:
    Bcl-xL degrader
    Apply
    Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma (NCT06620302)
    Phase 1/2
    Children's Oncology Group
    Not yet recruiting
    Last update posted :
    02/13/2025
    Initiation :
    03/20/2025
    Primary completion :
    12/30/2031
    Completion :
    12/30/2031
    BCL2 • DNAJB1 • PRKACA
    |
    irinotecan • DT2216